CP and cancer: We believe this difference in performance is related to the lesser LCs and enhanced physical and chemical stabilities of CPS-HMP NPs (ionotropic and covalent) compared to their CP-PPA analogs, which seem to reduce the rate of DOX release inside cancer cells.